Shares of Biogen Inc. BIIB slipped 4.09% to $116.82 Tuesday, on what proved to be an all-around grim trading session for the ...

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product ...

Biogen stock could pop Thursday after the biotech company beat first-quarter expectations, including strong sales for two newcomer drugs.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Biogen reported a mixed financial performance with Q1 2025 earnings illustrating a decline in net income and EPS compared to the prior year, while revenue saw an increase. This week's share price ...

In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...

Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.